Skip to main content
    I

    InterCure Ltd. (INCR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.64
    -0.15 (-3.96%)

    Market Cap: $49.17M

    Last updated: Nov 17, 2026 at 10:48 AM ET

    InterCure Ltd. (INCR) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in ILS.

    InterCure reported revenue of ILS 270.20M for the fiscal year ended Dec 31, 2025, up 13.1% from the year before. That year, net income was ILS -35.71M with a net margin of -13.2%, operating cash flow was ILS 16.84M and free cash flow was ILS 13.29M. The quarter ended Mar 31, 2026 had revenue of ILS 70.09M and net income of ILS -17.00M.

    Revenue and Margins

    The operating margin was 2.5% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from ILS 8.93M, a compound annual rate of 76.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025270.20M+13.1%12.3%2.5%-13.2%
    Dec 2024238.84M-32.8%12.7%-28.1%-28.4%
    Dec 2023355.55M-8.5%29.6%-11.7%-17.4%
    Dec 2022388.68M+76.9%39.9%13.0%11.5%
    Dec 2021219.68M+237.8%41.5%12.8%2.1%
    Dec 202065.03M+628.6%49.2%-59.0%-57.2%
    Dec 20198.93MN/A16.6%-38.3%-66.0%
    Dec 20180N/AN/AN/AN/A
    Dec 20170N/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue270.20M238.84M355.55M388.68M219.68M65.03M8.93M00N/A
    Cost of revenue237.02M208.61M250.46M233.60M128.55M33.06M7.45MN/A0N/A
    Gross profit33.18M30.23M105.09M155.08M91.13M31.98M1.48MN/A0N/A
    Research and development390.00K414.00K388.00K632.00K1.24M1.58M1.71M000
    Operating income6.73M-67.21M-41.57M50.63M28.19M-38.40M-3.42M-10.62M-3.98M1.20M
    Net income-35.71M-67.80M-61.96M44.82M4.69M-37.23M-5.89M-12.80M-5.26M265.42K
    EBITDAN/A-51.31M-23.90M70.23M31.17M-34.53MN/A-10.12M-1.15MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Revenue70.09M70.09M65.01M65.01M56.56M62.87M62.87M73.47M102.44M106.17M105.61M100.57M
    Gross profit239.50K239.50K20.11M20.11M195.50K20.83M20.83M18.16M32.64M34.33M25.86M46.21M
    Operating income-16.48M-16.48M2.86M2.86M-38.86M5.26M5.26M-26.67M5.82M5.95M-1.57M16.18M
    Net income-17.00M-17.00M-852.00K-852.00K-34.61M716.50K716.50K-33.53M4.88M214.00K5.27M7.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of ILS 163.52M exceeded cash and equivalents by 117.06M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets690.55M762.57M786.61M958.01M686.32M326.27M282.23M35.92M23.95M27.73M
    Current assets316.75M391.80M418.80M527.49M336.16M76.65M42.21M4.96M2.48M3.28M
    Cash and equivalents46.47M78.32M101.14M232.59M196.22M37.89M27.34M3.42M2.12M2.80M
    Total liabilities294.19M364.90M329.55M436.53M227.13M34.16M26.03M16.26M3.27M3.67M
    Short-term debt104.06M74.22M92.83M132.37M75.59M2.55M13.85M12.78M2.94M2.39M
    Long-term debt59.46M113.98M82.20M99.68M11.95M629.00K436.00KN/AN/AN/A
    Shareholder equity396.52M396.97M455.11M501.31M448.03M274.51M255.97M19.66M20.68M24.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets690.55M690.55M690.55M751.76M751.76M762.57M762.57M740.89M740.89M786.61M786.61M841.85M
    Total liabilities294.19M294.19M294.19M319.52M319.52M364.90M364.90M278.77M278.77M329.55M329.55M314.19M
    Cash and equivalents46.47M46.47M46.47M51.33M51.33M78.32M78.65M19.90M19.90M101.14M101.14M102.65M
    Shareholder equity396.52M396.52M396.52M431.15M431.15M396.97M396.97M460.44M460.44M455.11M455.11M508.76M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 78.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow16.84M-66.93M-53.63M51.27M25.02M7.80M-4.01M-1.49M-921.03KN/A
    Capital expenditures3.55M4.38M2.62M19.74M14.03M20.84M1.00K93.00K93.00KN/A
    Free cash flow13.29M-71.30M-56.25M31.52M10.99M-13.04M-4.01M-1.58M-1.01MN/A
    Investing cash flow-1.99M17.69M4.77M-142.50M-65.21M-22.76M-38.54M-7.96M-2.26MN/A
    Financing cash flow-46.66M26.45M-82.89M120.45M197.94M25.29M66.17M10.61M2.86M12.27M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow16.84M2.32M6.10M6.10MN/A-21.74M-21.74MN/AN/A949.00K-52.54M43.16M
    Capital expenditures3.55M152.00K1.62M1.62M0178.00K178.00K003.81K688.00K4.68M
    Free cash flow13.29M2.17M4.48M4.48MN/A-21.92M-21.92MN/AN/A945.19K-53.23M38.48M
    Last 12 quarters

    Frequently Asked Questions About INCR

    What is InterCure's annual revenue?

    InterCure reported revenue of ILS 270.20M for the fiscal year ended Dec 31, 2025.

    How fast is InterCure's revenue growing?

    Revenue was up 13.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -11.4%.

    Is InterCure profitable?

    No. InterCure reported net income of ILS -35.71M for the fiscal year ended Dec 31, 2025, with a net margin of -13.2%.

    How much free cash flow does INCR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of ILS 16.84M minus capital expenditures of ILS 3.55M produced free cash flow of ILS 13.29M.

    How much debt does InterCure have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of ILS 59.46M, short-term debt of ILS 104.06M and cash and equivalents of ILS 46.47M.